

SKYEPHARMA PLC  
Form 6-K  
June 02, 2003

**SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF  
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of June, 2003

SkyePharma PLC

---

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

---

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-  
\_\_\_\_\_

---

For Immediate Release

**SkyePharma PLC**

**Notification of Interests of Directors**

## Edgar Filing: SKYEPHARMA PLC - Form 6-K

The Company was informed on 30 May 2003 by Mr Ian Gowrie-Smith, Executive Chairman of SkyePharma PLC, that on 30th May 2003 6,000,000 Ordinary Shares from his beneficial holding in the Company had been sold at a price of 53 pence per share to meet part of the obligations previously referred to in the Directors' Interests section of the Company's Annual Report. As a result of the transaction Mr Gowrie-Smith now has a beneficial interest in 19.3 million Ordinary Shares in the Company (subject to the proposed transfer previously disclosed in the Annual Report).

ends

**SkyePharma Plc**

Peter Laing, Director of Corporate Communications

+ 44 (0) 20 7491 1777

**US Investor Relations**

Sandra Haughton

+ 1 (212) 753-5780

**Buchanan Communications**

Tim Anderson / Nicola How

+44 (0) 20 7466 5000

END

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**SkyePharma PLC**

By: /s/ Douglas Parkhill

Name: Douglas Parkhill

Title: Company Secretary

Date: June 2, 2003